Advertisement
Advertisement

MIRM

MIRM logo

Mirum Pharmaceuticals, Inc. Common Stock

96.72
USD
Sponsored
+0.41
+0.43%
Aug 24, 16:00 UTC -4
Closed
exchange

After-Market

96.76

+0.04
+0.04%

MIRM Earnings Reports

Positive Surprise Ratio

MIRM beat 13 of 29 last estimates.

45%

Next Report

Date of Next Report
Oct 29, 2026
Estimate for Q3 26 (Revenue/ EPS)
$181.08M
/
-$0.63
Implied change from Q2 26 (Revenue/ EPS)
+2.75%
/
-40.57%
Implied change from Q3 25 (Revenue/ EPS)
+36.14%
/
-1360.00%

Mirum Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Aug 05, 2026, MIRM reported earnings of -1.06 USD per share (EPS) for Q2 26, missing the estimate of -0.69 USD, resulting in a -52.65% surprise. Revenue reached 176.24 million, compared to an expected 169.44 million, with a 4.01% difference. The market reacted with a -11.04% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.63 USD, with revenue projected to reach 181.08 million USD, implying an decrease of -40.57% EPS, and increase of 2.75% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
$0.11
Actual
$0.35
Surprise
+198.38%
logo
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
logo
Abeona Therapeutics Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-49.19%
logo
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
logo
Alpha Cognition Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.40
Surprise
-0.05%
logo
ProMIS Neurosciences Inc. Common Shares (ON)
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.39
Actual
-$1.28
Surprise
+8.07%
logo
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
logo
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
logo
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
logo
PDS Biotechnology Corporation Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.18
Surprise
-35.75%
FAQ
For Q2 2026, Mirum Pharmaceuticals, Inc. Common Stock reported EPS of -$1.06, missing estimates by -52.65%, and revenue of $176.24M, 4.01% above expectations.
The stock price moved down -11.04%, changed from $105.79 before the earnings release to $94.11 the day after.
The next earning report is scheduled for Oct 29, 2026.
Based on 10 analysts, Mirum Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.63 and revenue of $181.08M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement